App-Quantinova.ai

Cisplatin-Induced Cardiac Macrophage Inflammatory Programs Unveiled With Single Cell Sequencing

Hua Pan - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Cisplatin

Vascular Events Associated With Cisplatin Based Combination Therapy An Analysis From Faers Database

Chitsimann Mann - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Cisplatin

Renalase Peptide Agonist Therapy Normalizes the Cardiac Response to Pressure Overload in Chronic Kidney Disease

Govind Krishna Kumar Nair - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Chronic kidney disease

Cisplatin

ACUTE CORONARY SYNDROME FOLLOWING TESTICULAR CANCER CHEMOTHERAPY: IS TREATMENT WORSE THAN DISEASE?

Axel Hiram Hernandez-Pineda - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Heart failure with reduced ejection fraction

Cisplatin

CARDIOMYOPATHY IN ADRENOCORTICAL CARCINOMA:IS IT CORTICOSTEROIDS OR CHEMOTHERAPY

Emmanuel Fohle - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Adrenal carcinoma

Cisplatin

Lipid-related anti-cancer drug resistance of lung adenocarcinoma cells

Anna Gründing - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Cisplatin

Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study

Rolof G.P. Gijtenbeek - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Cisplatin

Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).

Markus H. Moehler - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Cisplatin

HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma— Overall survival analysis.

Marina Maglakelidze - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

Cisplatin

Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648.

Ken Kato - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Cisplatin

Neo-AEGIS (Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Final primary outcome analysis.

John V. Reynolds - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal Cancer

Cisplatin

Short-term safety of adjuvant nivolumab therapy after neoadjuvant docetaxel plus cisplatin and 5-FU therapy for locally advanced esophageal squamous cell carcinoma.

Toshiharu Hirose - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Cisplatin

Docetaxel-based triplet neoadjuvant therapy for esophageal adenocarcinoma: A comprehensive analysis of outcomes spanning over a decade.

James Tankel - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal Cancer

Cisplatin

The new prognostic index of advanced gastric cancer using the data from JCOG1013.

Daisuke Takahari - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Cisplatin

Preoperative camrelizumab combined with chemotherapy for borderline resectable esophageal squamous cell carcinoma (BRES-1): A single-arm, open-label, phase II study.

Hang Yang - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Cisplatin

SHR-1701 plus chemotherapy as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

yi wang - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Cisplatin

Anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment (NAT) for esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, phase II clinical trial.

Yan-Feng Zhang - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Cisplatin

Updated results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase II clinical trial.

Ning Li - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Cisplatin

Anlotinib combined with paclitaxel and cisplatin as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC).

Gongqian Jiang - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Cisplatin

A multicenter randomized controlled trial of esophagectomy with or without prophylactic supraclavicular node dissection: A phase III trial (JCOG2013, MODERN3).

Shigeru Tsunoda - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Cisplatin

Filters

3952 Abstracts